MX3277E - Procedimiento para la preparacion de derivados de eritromicina - Google Patents

Procedimiento para la preparacion de derivados de eritromicina

Info

Publication number
MX3277E
MX3277E MX000145U MX14576U MX3277E MX 3277 E MX3277 E MX 3277E MX 000145 U MX000145 U MX 000145U MX 14576 U MX14576 U MX 14576U MX 3277 E MX3277 E MX 3277E
Authority
MX
Mexico
Prior art keywords
group
carbon atoms
moiety
alcohol
general formula
Prior art date
Application number
MX000145U
Other languages
English (en)
Inventor
Wolfgang Reuter
Roland Maier
Eberhard Woitun
Bernd Wetzel
Original Assignee
Thomae Gmbh Dr K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25768725&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX3277(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2515075A external-priority patent/DE2515075C2/de
Priority claimed from DE19762606030 external-priority patent/DE2606030A1/de
Application filed by Thomae Gmbh Dr K filed Critical Thomae Gmbh Dr K
Publication of MX3277E publication Critical patent/MX3277E/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08Hetero rings containing eight or more ring members, e.g. erythromycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un procedimiento para la preparación de derivados de eritromicina de las fórmulas I, IA y Ib; (ver gaceta) en las que R posee los siguientes significados: el grupo hidroxi, el grupo fenoxi, un grupo fenilalcoxi con 1 a 3 átomos de carbono en la porción alcohileno, un grupo alcoxi con 1 a 4 átomos de carbono, un grupo hidroxialcoxi, alcoxialcoxi, dialcohilaminoalcoxi o alcoxicarbonilalcoxi con 1 a 4 átomos de carbono en la porción alcohileno y 1 a 3 átomos de carbono en la porción alcohilo, el grupo mercapto, el grupo fenilmercapto, que eventualmente puede estar sustituido con grupos metilo, metoxi, etoxi isopropoxi o propoxi, un grupo fenilalcohilmercapto con 1 a 3 átomos de carbono en la porción alcohileno, un grupo alcohilmercapto de cadena recta o ramificada con 1 a 5 átomos de carbono, el grupo ciclohexilmercapto, un grupo hidroxialcohilmercato, dialcohilaminoalcohilmercapto, alcoxicarbonilalcohilmercapto o cianoalcohilmercapto en cada caso con 1 a 3 átomos de carbono en la porción alcohileno y en la porción alcohilo, un grupo amino de la fórmula general -NR2R3, en la queØR2 y R3, que pueden ser iguales o diferentes entre sí, representan átomos de hidrógeno, grupos fenilo, grupos fenilalcohilo con 1 a 3 átomos de carbono en la porción alchoileno, grupos alcohilo con 1 a 4 átomos de carbono, pudiendo formar los grupos alcohilo también conjuntamente con el átomo de nitrógeno situado entre medias un anillo heterocíclico monocíclico de 5 ó 6 miembros, que eventualmente puede estar interrumpido por un átomo de oxígeno o de azufre o por otro átomo de nitrógeno; un radical aciloxi de la fórmula general (ver gaceta), en la que R4 significa un grupo alcohilo de cadena recta o ramificada con 1 a 5 átomos de carbono, el grupo bencilo o el grupo fenilo; un grupo amido de la fórmula general -NH-CO-R5, en la que R5 significa un grupo alcohilo de cadena recta o ramificada con 1 a 5 átomos de carbono, que eventualmente puede estar sustituído con 1 ó 2 átomos de halógeno o con un grupo ciano, un grupo fenilalcohilo con 1 a 3 átomos de carbono en la porción alcohileno, que puede estar sustituído eventualmente en el radical fenilo con 1 ó 2 átomos de halógeno o un grupo metoxi y en la porción alcohileno con un átomo de halógeno, un radical fenoxiacohilo con 1 a 3 átomos de carbono en la porción alcohileno, un grupo fenilalquenilo con 2 a 4 átomos de carbono en la porción alquenileno, un grupo fenilo que eventualmente puede estar sustituído con uno o varios grupos metilo, hidroxi, metoxi o nitro o átomos de cloro; el grupo piridilo, furilo, fluorofurilo o tienilo, el radical N-fenilcarbamoílo, un radical carboxamido-metiloxi de la fórmula general (gaceta) en la que R6 y R7, que pueden ser iguales o diferentes entre sí, significan el grupo metilo, etilo, propilo o isopropilo, o un grupo dialcohilfosfono de la fórmula general(R8O)2-P en la que R8 representa un grupo alcohilo de cadena recta o ramificada con 1 a 5 átomos de carbono; un grupo sulfonamido de la fórmula general -NH-SO2-R9, en la que R9 significa un grupo alcohilo con 1 a 4 átomos de carbono o al radical fenilo eventualmente sustituído con un grupo alcohilo con 1 a 3 átomos de carbono,(ver gaceta)
MX000145U 1975-04-07 1976-04-06 Procedimiento para la preparacion de derivados de eritromicina MX3277E (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE2515075A DE2515075C2 (de) 1975-04-07 1975-04-07 Erythromycinderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE19762606030 DE2606030A1 (de) 1976-02-14 1976-02-14 Neue erythromycinderivate und verfahren zu ihrer herstellung

Publications (1)

Publication Number Publication Date
MX3277E true MX3277E (es) 1980-08-15

Family

ID=25768725

Family Applications (1)

Application Number Title Priority Date Filing Date
MX000145U MX3277E (es) 1975-04-07 1976-04-06 Procedimiento para la preparacion de derivados de eritromicina

Country Status (29)

Country Link
US (1) US4048306A (es)
JP (1) JPS51128991A (es)
AT (1) AT342770B (es)
AU (1) AU498418B2 (es)
BG (1) BG27380A3 (es)
CA (1) CA1060005A (es)
CH (2) CH621800A5 (es)
CS (1) CS196304B2 (es)
DD (1) DD125218A5 (es)
DK (1) DK138656C (es)
ES (2) ES446737A1 (es)
FI (1) FI63244C (es)
FR (1) FR2306703A1 (es)
GB (1) GB1520963A (es)
GR (1) GR60374B (es)
HU (1) HU175186B (es)
IE (1) IE43598B1 (es)
IL (1) IL49359A (es)
LU (2) LU88563I2 (es)
MX (1) MX3277E (es)
NL (1) NL180107C (es)
NO (1) NO141411C (es)
NZ (1) NZ180529A (es)
PL (1) PL101880B1 (es)
PT (1) PT64977B (es)
RO (1) RO68441B (es)
SE (1) SE425566B (es)
SU (1) SU682134A3 (es)
YU (1) YU87676A (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES552858A1 (es) 1985-03-12 1987-11-01 Beecham Group Plc Un procedimiento para la preparacion de derivados de eritromicina.
DE3524572A1 (de) * 1985-07-10 1987-01-15 Thomae Gmbh Dr K Feste arzneimittelformen zur peroralen anwendung enthaltend 9-deoxo-11-deoxy-9,11-(imino(2-(2-methoxyethoxy)ethyliden)-oxy)-(9s)-erythromycin und verfahren zu ihrer herstellung
US5110800A (en) * 1986-02-18 1992-05-05 Eli Lilly And Company Derivatives of erythromycylamine
US4945080A (en) * 1987-05-26 1990-07-31 Eli Lilly And Company Dirithromycin metabolite
US5075289A (en) * 1988-06-07 1991-12-24 Abbott Laboratories 9-r-azacyclic erythromycin antibiotics
EP0559896B1 (en) * 1990-11-28 1997-08-27 Taisho Pharmaceutical Co. Ltd 6-o-methylerythromycin a derivative
ZA922777B (en) * 1991-04-29 1993-10-15 Lilly Co Eli Pharmaceutical formulation containing dirithromycin
US5556839A (en) * 1991-04-29 1996-09-17 Eli Lilly And Company Form II Dirithromycin
CZ281664B6 (cs) * 1991-09-30 1996-12-11 Eli Lilly And Company Patent Division Lilly Corporate Center Způsob jednostupňové přípravy dirithromycinu
DE4410637C1 (de) * 1994-03-26 1995-09-21 Boehringer Ingelheim Vetmed Injizierbare Lösungen von Dirithromycin
WO1999021867A1 (fr) * 1997-10-29 1999-05-06 Taisho Pharmaceutical Co., Ltd. Derives d'erythromycine a
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6565882B2 (en) 2000-02-24 2003-05-20 Advancis Pharmaceutical Corp Antibiotic composition with inhibitor
US6541014B2 (en) 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6436906B1 (en) 2001-04-02 2002-08-20 Enanta Pharmaceuticals, Inc. 9-amino-14-membered macrolides derived from leucomycins
AU2004258949B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
CA2533292C (en) 2003-07-21 2013-12-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
AU2004258944B2 (en) 2003-07-21 2011-02-10 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP2007502296A (ja) 2003-08-11 2007-02-08 アドバンシス ファーマスーティカル コーポレイション ロバストペレット
US8062672B2 (en) 2003-08-12 2011-11-22 Shionogi Inc. Antibiotic product, use and formulation thereof
WO2005023184A2 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
WO2005027877A1 (en) 2003-09-15 2005-03-31 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8299052B2 (en) * 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660376A (en) * 1970-09-30 1972-05-02 Lilly Co Eli N-arylidene erythromycylamines

Also Published As

Publication number Publication date
BG27380A3 (en) 1979-10-12
SE7604052L (sv) 1976-10-08
IL49359A0 (en) 1976-06-30
NL180107C (nl) 1987-01-02
IE43598L (en) 1976-10-07
NL7603569A (nl) 1976-10-11
HU175186B (hu) 1980-05-28
PT64977A (de) 1976-05-01
RO68441A (ro) 1983-04-29
DK138656B (da) 1978-10-09
PL101880B1 (pl) 1979-02-28
PT64977B (de) 1978-04-03
SU682134A3 (ru) 1979-08-25
NO141411B (no) 1979-11-26
FR2306703A1 (fr) 1976-11-05
ES446737A1 (es) 1977-10-16
US4048306A (en) 1977-09-13
GR60374B (en) 1978-05-23
IE43598B1 (en) 1981-04-08
GB1520963A (en) 1978-08-09
CH624413A5 (es) 1981-07-31
CH621800A5 (es) 1981-02-27
NL180107B (nl) 1986-08-01
LU74702A1 (es) 1977-06-03
RO68441B (ro) 1983-04-30
YU87676A (en) 1982-08-31
IL49359A (en) 1979-07-25
SE425566B (sv) 1982-10-11
AT342770B (de) 1978-04-25
NZ180529A (en) 1978-09-20
FI760845A (es) 1976-10-08
FR2306703B1 (es) 1979-10-12
ATA149976A (de) 1977-08-15
FI63244B (fi) 1983-01-31
FI63244C (fi) 1983-05-10
JPS62158B2 (es) 1987-01-06
AU498418B2 (en) 1979-03-15
NO141411C (no) 1980-03-05
CS196304B2 (en) 1980-03-31
DD125218A5 (de) 1977-04-06
DK145276A (da) 1976-10-08
JPS51128991A (en) 1976-11-10
NO761172L (es) 1976-10-08
DK138656C (da) 1979-04-02
LU88563I2 (fr) 1995-03-21
AU1272276A (en) 1977-10-13
CA1060005A (en) 1979-08-07
ES456567A1 (es) 1978-03-01

Similar Documents

Publication Publication Date Title
MX3277E (es) Procedimiento para la preparacion de derivados de eritromicina
JPS51115478A (en) Piperidine derivatives acid addidion salt and optical isomer
ES462062A1 (es) Un procedimiento para la preparacion de nuevos derivados de tetrahidroisoquinoleina.
ES403503A1 (es) Procedimiento para la preparación de derivados de piperidina y su utilizacion como estabilizadores
ES278320A1 (es) Procedimiento para la preparación de compuestos de poliadición estables a la luz
CO5690585A2 (es) Uso de inhibidores de la ikb-quinasa para el tratamiento del dolor
ES387016A1 (es) Un procedimiento para la preparacion de derivado de isoqui-nolina.
BG26526A3 (bg) Метод за получаване на 1-(бензазолилалкил)пиперидинови производни
SE7604593L (sv) Anordning vid en overladdad forbrenningmotor
ES470861A1 (es) Procedimiento de preparacion de derivados de benzoil-2 clo- ro-4 glicinanilidas
DK340476A (da) Thiazolidinderivater og fremgangsmade til deres fremstilling
DK219488D0 (da) Benzo- og thieno-3,4-dihydropyridinderivater, deres fremstilling og laegemidler indeholdende forbindelserne
SE7501340L (sv) Anordning vid forgasare serskilt for forbrenningsmotorer
ES369746A1 (es) Procedimiento de obtencion de derivados de aminopiperidina.
ES452648A1 (es) Un procedimiento para la preparacion de nuevos derivados de 3,5-diona-4,4-dimetil-pirrolidina.
SE7607300L (sv) Tiaxantenforeningar samt forfarande for framstellning av dem
ES410934A1 (es) Procedimiento para la preparacion de acidos indolcarboxili-cos.
ES444036A1 (es) Procedimiento de preparacion de la (tienil-2)-2-etilamina y sus derivados.
ES383467A1 (es) Procedimiento para la preparacion de derivados de pirrol.
ES428600A1 (es) Procedimiento de preparacion de fenilpiperazino-1 amino-3 propanoles-2.
SE392831B (sv) Anordning vid inmatningsbenkar for kantverk
ES420760A1 (es) Procedimiento para laobtencion de composiciones desensibi- lizadoras.
ES426329A1 (es) Un procedimiento para la preparacion de nuevos derivados de 1,2,3,4-tetrahidroisoquinoleina.
ES280829A1 (es) Procedimiento de preparación de derivados de la amino-4 quinoleína
ES426330A1 (es) Un procedimiento para la preparacion de nuevos derivados de1,2,3,4-tetrahidroisoquinoleina.